Shop by Category

Diagnostic Conjugates Development & Manufacturing

diagnostic bioconjugate

CellMosaic offers research and process development services for diagnostic or medical imaging companies interested in developing highly specific diagnostic bioconjugates. CellMosaic's scientists have extensive experience in developing fluorescent-, antibody-, peptide-, and oligonucleotide-based detection agents. We provide a complete solution for the development of your diagnostic bioconjugate, including:

  • Custom design and development of conjugation strategies to fit your needs.
  • Feasibility studies: Synthesis of the linker molecules, modification of biomolecules, and evaluation of the conjugation chemistry.
  • Process development.
  • Development of a purification method for diagnostic bioconjugates.
  • Development of bio-analytical methods.
Examples of Diagnostic Bioconjugates:

1. Antibody- and Antibody Fragment-Based Agent

Based on the unique conjugation strategy developed at CellMosaic, we offer site-specific antibody labeling and conjugation for diagnostic companies. A small detection agent or biopolymer can be conjugated to an antibody at a specific site away from the antigen binding site.

Comparison of labeling technologies:

Traditional antibody labeling technologies usually take advantage of the multiple Lys groups located in the antibody. Modification of the Lys groups changes the overall pI of the antibody and leads to higher nonspecific binding. In addition, if some of the modified or conjugated Lys residues are located on the antigen binding sites this method may produce partially active or inactive antibody conjugates that may not bind to the antigen. 

Disadvantages of traditional Lys labeling technology are:

  • Multiple labeling of antibody and a heterogeneous pool of labeled-antibodies.
  • Lower antigen binding affinity corresponding to a weaker signal.
  • Nonspecific binding and a high background signal.

Advantages of CellMosaic's site-specific labeling technology:

  • Labeling of the antibody at single or few predictable sites
  • Retained antigen binding affinity corresponding to stronger signal.
  • Higher specificity and low background noise.

2. Epitope-Based Detection:

CellMosaic prepares peptide-epitope conjugates based on a unique conjugation strategy developed at CellMosaic. Detection molecules can be conjugated anywhere on the peptide (C-terminus, N-terminus, or in the middle). Usually, a single, pure bioconjugate can be obtained. The whole process can easily be tailored to fit a client's project. This is a fast approach and great solution for clients who want to develop peptide-based conjugates.

Advantages of CellMosaic's peptide conjugation strategy:

  • Freedom to attach detection molecule at any point of the peptide.
  • Other functional groups, such as OH, NH2, and SH, in the peptide will not be affected by the conjugation step.
  • The conjugation strategy can easily be tweaked to couple to different categories of compounds.
  • Short timeline for development of the bioconjugation strategy.

 3. Enzyme-Based Bioconjugates

Using the unique conjugation strategy developed at CellMosaic, we offer site-specific enzyme labeling and conjugation for diagnostic companies. A small detection agent or biopolymer can be conjugated to an enzyme at a specific site.

Comparison of labeling technologies:

Conventional labeling technology usually takes advantage of the multiple Lys groups located in the enzyme. Modification of the Lys groups changes the overall pI of the enzyme and leads to higher nonspecific binding.

Disadvantages of conventional Lys labeling technology are:

  • Labeling of multiple enzyme sites and a heterogeneous pool of enzyme conjugates.
  • Modification of enzyme properties with decreased activity and weaker signal.
  • Nonspecific enzymatic reactions, which may produce higher background noise.

Advantages of CellMosaic's site-specific labeling technology:

  • Labeling of enzyme at a single or few predictable sites.
  • Retained enzyme activity and stronger signal.
  • Higher specificity and lower background noise.

 4.  Oligonucleotide-Based Bioconjugates

CellMosaic offers versatile oligonucleotide labeling and conjugation strategies, depending on the application profile of the diagnostic companies' reagent portfolio. A small detection agent or biopolymer can be conjugated to any site of the oligonucleotide (3', 5', or via a modified base). The conjugation can be done in either the solid phase or post-synthesis solution phase.

Please contact us to discuss your project.

Selected examples of diagnostic bioconjugates made at CellMosaic:

There are no products listed under this category.